Latest News
Merck launches Phase 3 trial of Ohtuvayre for COPD exacerbation prevention
3 November 2026 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Tuesday that it has initiated ENHANCE-3, a Phase 3 clinical trial evaluating Ohtuvayre (ensifentrine) for preventing chron...
Vivesto secures US orphan drug designation for Cantrixil in acute myeloid leukemia
3 November 2026 - Swedish oncology-focused development company Vivesto AB (STO:VIVE) said on Tuesday that it has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for Cantrixil as a treatment for acute myeloid leuk...
Lytix Biopharma's ruxotemitide combination meets primary endpoint in Phase II melanoma trial
3 November 2026 - Clinical-stage biotech company Lytix Biopharma ASA (Euronext Growth Oslo:LYTIX) announced on Tuesday that its Phase II NeoLIPA study evaluating ruxotemitide in combination with pembrolizumab in patients with resectable melanoma has ...
Asker Healthcare Group acquires Estonia's Teresa OÜ
3 November 2026 - Swedish healthcare group Asker Healthcare Group AB (STO: ASKER), which provides medical products and solutions across Europe, said on Tuesday it has acquired 100% of the shares in Teresa OÜ, an Estonian supplier of mobility aid...
Ultima Genomics UG200 Sequencing Platform selected for SG-INSIGHT study
3 November 2026 - US biotechnology company Ultima Genomics announced on Monday that its UG200 Sequencing Platform has been selected for the SG-INSIGHT study, a cohort under Phase III of Singapore's National Precision Medicine (NPM) programme, a ...